Pablo Canales-Herrerias

Excited to share our new work in @SciImmunology! We describe targeting of gut-associated lymphoid tissue (GALT) as a novel mode of action of anti-α4β7 therapy in IBD. Co-led by @mat_uzz & A. Seki @MehandruLab @SinaiImmunol @MountSinaiGI @IcahnMountSinai🧵 science.org/doi/10.1126/sc…

Excited to be starting my research group as a tenure track Presidential Young Professor at the Mechanobiology Institute @MBIsg, and the Dept of Physiology at @NUSingapore in the fall! More about our work on vascular mechanobiology: mechano-medicine-lab.com

Interested in pursuing a PhD thesis in our group in Demark? Interested in droplets, immune cells and cellular functions? Then definitely apply! phd.health.au.dk/application/op…

Please RT 🙏!📢My lab at @UniBarcelona is seeking a highly motivated postdoc to lead an exciting new public-private collaborative project (UB, CRG, CSIC, OrikineBio) aimed at testing a potentially game-changing therapy for IBD. If interested, please contact me at [email protected].

Intestinal germinal center B cell reduction in HIV-1 infection is linked to reduced IgA+ plasma cells and systemic inflammation @SciImmunology @francescacossa1 @saurabhmehandru science.org/doi/10.1126/sc…

Check this out from @francescacossa1 and @MehandruLab 🔥🔥 @SinaiImmunol @MountSinaiGI @SciImmunology 👇

🎉 Applications are open for the 2025 Pasteur-Paris University PhD Program (PPU)! Join a global community of researchers and contribute to groundbreaking biomedical discoveries. 📅 Deadline: October 27, 2024 🔗 Apply now: pasteur.fr/en/education/p… #research #institutpasteur

According to a Mount Sinai study, Vedolizumab, a mainstay drug for managing ulcerative colitis, appears to work by targeting gut-associated lymphoid tissue. Read more: mshs.co/3zacgc0 @DOMSinaiNYC @MountSinaiGI #IBD

We are looking for post-docs. Interested in early life human immunity and bioinformatics? We have a number of really interesting projects. Spread the word and please apply! @YalePediatrics @YaleIBIO

Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive medicalxpress.com/news/2024-07-f… via @medical_xpress

Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive (Vdz) medicalxpress.com/news/2024-07-f… via @medical_xpress

Out now 🚨 in @AGA_Gastro is your latest update on selective IL-23p19 inhibition in IBD! Amongst other topics featuring discussion of pathogenesis, PD/PK, efficacy, safety, positioning, and more! Together with @JeanFredericCo1 @MehandruLab & @ryanungaro gastrojournal.org/article/S0016-…

Gut-associated lymphoid tissue may shape drugs' efficacy. .@pabloimmune & colleagues describe targeting of gut-associated lymphoid tissue as a novel mode of action of anti-α4β7 therapy in IBD via @SciImmunology: science.org/doi/10.1126/sc…

Thank you for the highlight @ScienceMagazine! 🔦 science.org/doi/10.1126/sc… 📄science.org/doi/10.1126/sc…

How does vedolizumab work in ulcerative colitis patients? Researchers in a new @SciImmunology study say the drug targets gut-associated lymphoid tissue. Learn more: scim.ag/6KJ

How does vedolizumab work in ulcerative colitis patients? Researchers in a new @SciImmunology study say the drug targets gut-associated lymphoid tissue. Learn more: scim.ag/6Im

Explore Dr. Saurabh Mehandru's latest research uncovering vedolizumab's impact on gut-associated lymphoid tissue (#GALT) in #IBD treatment. Gain fresh insights into therapeutic response mechanisms: bit.ly/3QiGUoJ

In ulcerative #colitis patients who respond to #vedolizumab, gut-associated lymphoid tissue shrinks and produces fewer inflammatory cells. Learn more: scim.ag/6Hr

Check out our new work in @SciImmunology! Gut-associated lymphoid tissue targeting in IBD. New insights into vedolizumab MOA @IcahnMountSinai @SinaiImmunol @MountSinaiGI

Amazing 🗞️ paper abt MoAction one of the most 🔐 precision biologic in #UlcerativeColitis treatment since 2015 🗝️ 🔓 #Vedolizumab 👉 Anti-α4β7 therapy results in a decrease ⬇️ of #naïve B & T cells in🎯 intestinal mucosa of #UC patients @SciImmunology doi.org/10.1126/sciimm…